Literature DB >> 12869018

Cryoglobulins in chronic hepatitis C virus infection.

M Trendelenburg, J A Schifferli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12869018      PMCID： PMC1808770          DOI： 10.1046/j.1365-2249.2003.02198.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  28 in total

1.  Two-dimensional electrophoretic analysis of cryoproteins: a report of 335 samples.

Authors:  J D Tissot; F Invernizzi; J A Schifferli; F Spertini; P Schneider
Journal:  Electrophoresis       Date:  1999-03       Impact factor: 3.535

2.  Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II.

Authors:  Y Kitay-Cohen; A Amiel; N Hilzenrat; D Buskila; Y Ashur; M Fejgin; E Gaber; R Safadi; R Tur-Kaspa; M Lishner
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

3.  Hepatitis C: a possible etiology for cryoglobulinaemia type II.

Authors:  A Pechère-Bertschi; L Perrin; P de Saussure; J J Widmann; E Giostra; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

4.  A calcium-dependent cryoglobulin IgM kappa/polyclonal IgG.

Authors:  M Qi; G Steiger; J A Schifferli
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

5.  Defective immune adherence and elimination of hepatitis B surface antigen/antibody complexes in patients with mixed essential cryoglobulinemia type II.

Authors:  N Madi; G Steiger; J Estreicher; J A Schifferli
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

Review 6.  CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.

Authors:  S Levy; S C Todd; H T Maecker
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

7.  Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas.

Authors:  M Ivanovski; F Silvestri; G Pozzato; S Anand; C Mazzaro; O R Burrone; D G Efremov
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

8.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

9.  Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia.

Authors:  F Dammacco; D Sansonno
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

10.  Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs.

Authors:  Salvatore De Vita; Valli De Re; Domenico Sansonno; Annunziata Gloghini; Daniela Gasparotto; Massimo Libra; Stefania Sacco; Antonino Carbone; Gianfranco Ferraccioli; Mauro Boiocchi
Journal:  Tumori       Date:  2002 Sep-Oct
View more
  4 in total

1.  Hepatitis C virus positive patient diagnosed after detection of atypical cryoglobulin.

Authors:  Belkiz Ongen; Fehime Benli Aksungar; Bahattin Cicek; Isin Akyar; Abdurrahman Coskun; Mustafa Serteser; Ibrahim Unsal
Journal:  World J Clin Cases       Date:  2016-03-16       Impact factor: 1.337

Review 2.  Understanding the Cryoglobulinemias.

Authors:  Alejandro Fuentes; Claudia Mardones; Paula I Burgos
Journal:  Curr Rheumatol Rep       Date:  2019-11-19       Impact factor: 4.686

3.  Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience.

Authors:  Amro M Hassan; Heba A Osman; Hasan S Mahmoud; Mohammed H Hassan; Abdel-Kader A Hashim; Hesham H Ameen
Journal:  Infect Drug Resist       Date:  2018-06-27       Impact factor: 4.003

4.  A rheumatoid factor paradox: inhibition of rituximab effector function.

Authors:  Jonathan D Jones; Irene Shyu; Marianna M Newkirk; William F C Rigby
Journal:  Arthritis Res Ther       Date:  2013-01-25       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.